Research and development of finished dosage forms

Highest demands on formulations and innovation through a wide range of technologies

Our in-house Research & Development form the bedrock of our purpose to deliver better healthcare. Grow your brand with added value for patients through best-in-class formulations that meet the needs of their markets!

The world´s most trusted brands count on our high excellence in pharmaceutical research and development, building the foundation for our broad and innovative product portfolio. Acting on the needs for better therapies and the everchanging market, we target generics as well as value added and innovative pharmaceutical products. Whether it´s fewer side effects, a better API absorption or a personalized drug dispensing device, we believe that there are always new ways of smart medicines which better deliver on patients´ needs. This pioneer spirit is driven by our curiosity – the curiosity of each of our employees dedicated to make patients´ lives better. To better understand patients´ needs we are in close and regular collaboration with universities and key opinion leaders of all relevant disciplines.

Our own laboratories, the long-lasting experience of our research & development staff, and our exclusive network of development partners enable us to cover all major indications as well as diverse and innovative dosage forms. We succeed in developing tablets, capsules, modified release formulations, oral and ophthalmic solutions as well as special technologies like patches, inhalers, injectables or personalized devices. Furthermore, we are committed to drive for growth and innovation with a well-defined and specialized portfolio of highly potent drug formulations. Our current entire portfolio consists of 180 products: 100 dossiers, 40 products under development, and 40 in our pipeline. Every year, we start the development of 10 to 15 promising new products – both niche products and blockbusters – to fuel our sustainable growth. Outstanding intellectual property (IP) guidance and quality assurance (QA) are the backbone of our Research & Development operations to deliver better affordable high-quality pharmaceuticals worldwide.

Tiefenbacher research and development: solutions that exceed expectations

Your benefits of our advanced Research & Development operations

We, at TIEFENBACHER GROUP, constantly adapt and track the latest insights, to let our curiosity and science show us the way forward in healthcare. 
Our research and development operations for better healthcare – by developing high-quality pharmaceuticals with added value for patients worldwide. We stand for reliability, the highest standards of safety and quality, and a forward-looking approach along the entire pharmaceutical value chain. Our capabilities span a wide range of development technologies and specialtiesall backed by comprehensive industry knowledge and experience for drug development and commercialization worldwide 

180 +

dossiers developed/ under development

generic, value added, and innovative drugs

all major indications and a specialized highly potent drug portfolio

broad spectrum of different dosage forms

180 +

products

generic and innovative formulations

all major indications

broad spectrum of different dosage forms

innovative and digital technologies

FDA approved own laboratory

outstanding intellectual property guidance

highly reliable quality assurance

innovative and digital technologies

FDA approved own laboratory

outstanding intellectual property guidance

highly reliable quality assurance

TIEFENBACHER Laboratories: our center of innovations

With advanced technologies to pharmaceuticals of the future

Our state-of-the-art, FDA approved laboratories in India for drug development and commercialisation worldwide.
The research and development operations for both generic and innovative formulations are supported by our advanced laboratory in Hyderabad, India. TIEFENBACHER LABORATORIES features a GLP/GMP compliant environment on a 32.000 m² sized plant. Most modern techniques and softwares (e. g. inhouse XRD Crystallography, WinNonlin IVIVC simulation tools, Nitrosamine testing, Malvern particle size testing) are part of the state-of-the-art research & development equipment. With our new own high potent lab we are committed to drive for growth and innovation and are able to develop a well-defined and specialized portfolio of highly potent drug formulations inhouse. This includes the development of tablets as well as capsules.

Quality control is an integral part of TIEFENBACHER LABORATORIES. It ensures a development process which considers all aspects of quality and customer requirements, transparency, and applying good manufacturing practice (GMP) – according to national as well as international legislation. The development projects are performed following ICH, EU, USFDA and other international guidelines. This enables us to generate a corresponding documentation for the submission of a marketing authorization application in the EU, in the US, and further international territories. TIEFENBACHER LABORATORIES holds the ISO 14001:2014 and ISO 18001:2015 certifications and was successfully inspected by the German BGV, the US FDA authorities, the Russian MIT, and the Turkish Ministry of Health.

We are experts and innovators to improve people’s life

New Generation of pharmaceuticals: our new state-of-the-art lab for highly potent drugs

TIEFENBACHER GROUP is now able to develop and manufacture highly potent drugs in its new dedicated site in Hyderabad, India. Our competence ranges from the first phase of research to the commercial production of drugs for the treatment of cancer and other conditions – for both tablets and capsules. The new state-of-the-art lab is equipped with the most modern techniques and software and will be supplemented by a new manufacturing block with special technologies in 2023. The whole complex will cover a total of about 4.000 square meters – to develop better therapies for a market entry worldwide.

TIEFENBACHER PHARMACEUTICALS (FDF business unit of TIEFENBACHER GROUP) has already 25 leading highly potent drugs in its launch pipeline which are planned to be developed and produced in-house in the new facilities in Hyderabad. While the operational start of the lab has already started (including small-scale production), the commercial production for larger quantities in the new manufacturing block is expected for 2024.

For more information about our highly potent competence and innovative technologies, please contact us at any stage of your inquiry – by filling out the contact form below on this webpage, or please directly send an email to info@aet.eu

TIEFENBACHER GROUP: We use innovative science and technology to improve people’s lives.  

Do not hesitate to get in touch for more information about our research & development solutions for better affordable high-quality pharmaceuticals worldwide. Our experts are always available to help – from the idea through drug development to commercialization.  
Please contact us by filling out the contact form below and clicking “Send message”. TIEFENBACHER GROUP will follow up with you personally as soon as possible.